Allergan

Has the Brent Saunders price-hike limit become a de facto pharma rule?
Has the Brent Saunders price-hike limit become a de facto pharma rule?
Fierce Pharma
Brent Saunders
Allergan
drug pricing
Flag link:
Allergan's Brent Saunders Is Charging Into Medical Aesthetics. Should Others Follow?
Allergan's Brent Saunders Is Charging Into Medical Aesthetics. Should Others Follow?
Forbes
Allergan
Brent Saunders
aesthetics
Pharma CEOs
Flag link:
FDA approves 4-year intrauterine device
FDA approves 4-year intrauterine device
Drug Delivery Business News
FDA
Allergan
IUD
devices
contraceptives
Liletta
Flag link:
Allergan ramps up promotion for new rosacea drug
Allergan ramps up promotion for new rosacea drug
Medical Marketing and Media
Allergan
Rosacea
Rhofade
CVS Health
Flag link:
Pfizer's Poor Earnings Feed the Allergan Tie-Up Fire
Pfizer's Poor Earnings Feed the Allergan Tie-Up Fire
TheStreet.com
Pfizer
earnings
Allergan
M&A
Flag link:
Botox, fillers steal the show as Allergan posts Q2 beats
Botox, fillers steal the show as Allergan posts Q2 beats
Fierce Pharma
Allergan
earnings
Flag link:
As Roche wades biosimilar waters, more competitors circle Herceptin
As Roche wades biosimilar waters, more competitors circle Herceptin
BioPharma Dive
Roche
Herceptin
biosimilars
Amgen
Allergan
ABP 980
Celltrion
CT-P6
Flag link:
Allergan can finally sell its losing stake in Teva. Will it?
Allergan can finally sell its losing stake in Teva. Will it?
Fierce Pharma
Allergan
Teva Pharmaceutical
Flag link:
FDA advances two more Herceptin biosims—this time from Amgen and Teva—as Roche braces for impact
FDA advances two more Herceptin biosims—this time from Amgen and Teva—as Roche braces for impact
Fierce Pharma
FDA
Herceptin
biosimilars
Roche
Amgen
Teva Pharmaceutical
Allergan
Celltrion
Flag link:
Allergan CEO comes out against aesthetic treatments for teens in debate-sparking blog post
Allergan CEO comes out against aesthetic treatments for teens in debate-sparking blog post
Fierce Pharma
Allergan
Pharma CEOs
aesthetics
Brent Saunders
Flag link:
Medtech Mergers Surge Again
Medtech Mergers Surge Again
Seeking Alpha
devices
M&A
Abbott Labs
Cutera
St. Jude Medical
Allergan
Syneron
JNJ
Flag link:
Can Allergan's spruced-up aesthetics lineup shake off 'meh' Kybella growth?
Can Allergan's spruced-up aesthetics lineup shake off 'meh' Kybella growth?
Fierce Pharma
Allergan
aesthetics
Kybella
Zeltiq
Rhofade
Flag link:
Eli Lilly Wins Cancer Drug Patent Case at U.K. Supreme Court
Eli Lilly Wins Cancer Drug Patent Case at U.K. Supreme Court
Bloomberg
Eli Lilly
patents
UK
Altima
Actavis
Allergan
Teva Pharmaceutical
Flag link:
Allergan inks $13M settlement in whistleblower marketing suit
Allergan inks $13M settlement in whistleblower marketing suit
Fierce Pharma
Allergan
kickbacks
physicians
dry eye disease
Restasis
whistleblower lawsuits
Flag link:
Allergan vet Doug Ingram takes the helm of a storm-tossed Sarepta
Allergan vet Doug Ingram takes the helm of a storm-tossed Sarepta
Endpoints
Allergan
Sarepta Therapeutics
Doug Ingram
Flag link:
Allergan reaches the masses via unbranded Botox Facebook page
Allergan reaches the masses via unbranded Botox Facebook page
Medical Marketing and Media
Allergan
Botox
Facebook
social media
Flag link:
Allergan picks up aesthetic device dev Keller Medical
Allergan picks up aesthetic device dev Keller Medical
Mass Device
Allergan
devices
M&A
Keller Medical
Flag link:
Ohio suit will be 'tough to win' for opioid drugmakers, analyst says
Ohio suit will be 'tough to win' for opioid drugmakers, analyst says
Fierce Pharma
Ohio
opioids
Teva
Allergan
JNJ
Purdue
Endo Health Solutions
Flag link:
Ohio attorney general sues 5 pharma companies over their role in the opioid epidemic
Ohio attorney general sues 5 pharma companies over their role in the opioid epidemic
CNBC
Ohio
opioid crisis
opioids
opioid abuse
JNJ
Janssen
Teva Pharmaceutical
Purdue Pharma
Allergan
Endo Health Solutions
Flag link:
3 Drug Stocks Billionaire Money Managers Dumped Big-Time in the First Quarter
3 Drug Stocks Billionaire Money Managers Dumped Big-Time in the First Quarter
Motley Fool
Teva Pharmaceutical
Allergan
Valeant Pharmaceuticals
Flag link: